Reply: considerations for drug development for heart failure.
Publication
, Journal Article
Greene, SJ; Gheorghiade, M
Published in: J Am Coll Cardiol
March 17, 2015
Duke Scholars
Published In
J Am Coll Cardiol
DOI
EISSN
1558-3597
Publication Date
March 17, 2015
Volume
65
Issue
10
Start / End Page
1061 / 1062
Location
United States
Related Subject Headings
- Relaxin
- Male
- Humans
- Heart Failure
- Female
- Death, Sudden, Cardiac
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Greene, S. J., & Gheorghiade, M. (2015). Reply: considerations for drug development for heart failure. J Am Coll Cardiol, 65(10), 1061–1062. https://doi.org/10.1016/j.jacc.2014.11.064
Greene, Stephen J., and Mihai Gheorghiade. “Reply: considerations for drug development for heart failure.” J Am Coll Cardiol 65, no. 10 (March 17, 2015): 1061–62. https://doi.org/10.1016/j.jacc.2014.11.064.
Greene SJ, Gheorghiade M. Reply: considerations for drug development for heart failure. J Am Coll Cardiol. 2015 Mar 17;65(10):1061–2.
Greene, Stephen J., and Mihai Gheorghiade. “Reply: considerations for drug development for heart failure.” J Am Coll Cardiol, vol. 65, no. 10, Mar. 2015, pp. 1061–62. Pubmed, doi:10.1016/j.jacc.2014.11.064.
Greene SJ, Gheorghiade M. Reply: considerations for drug development for heart failure. J Am Coll Cardiol. 2015 Mar 17;65(10):1061–1062.
Published In
J Am Coll Cardiol
DOI
EISSN
1558-3597
Publication Date
March 17, 2015
Volume
65
Issue
10
Start / End Page
1061 / 1062
Location
United States
Related Subject Headings
- Relaxin
- Male
- Humans
- Heart Failure
- Female
- Death, Sudden, Cardiac
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology